Treatment of Autoimmune Liver Disease: Current and Future Therapeutic Options

Overview

Journal Ther Adv Chronic Dis

Publisher Sage Publications

Date 2013 May 2

PMID 23634279

Citations 13

Authors

Palak J Trivedi

Gideon M Hirschfield

Affiliations

Soon will be listed here.

Abstract

Autoimmune liver disease spans three predominant processes, from the interface hepatitis of autoimmune hepatitis to the lymphocytic cholangitis of primary biliary cirrhosis, and finally the obstructive fibrosing sclerotic cholangiopathy of primary sclerosing cholangitis. Although all autoimmune in origin, they differ in their epidemiology, presentation and response to immunosuppressive therapy and bile acid based treatments. With an ongoing better appreciation of disease aetiology and pathogenesis, treatment is set ultimately to become more rational. We provide an overview of current and future therapies for patients with autoimmune liver disease, with an emphasis placed on some of the evidence that drives current practice.

Citing Articles

A Case of Hepatitis in Pregnancy.

Alfred-Demas R, Daisley H, Dalrymple N, Alfred R, Thompson-Dillon A Cureus. 2025; 16(12):e75861.

PMID: 39822480 PMC: 11736823. DOI: 10.7759/cureus.75861.

Scaffold-mediated liver regeneration: A comprehensive exploration of current advances.

Bhatt S S, Krishna Kumar J, Laya S, Thakur G, Nune M J Tissue Eng. 2024; 15:20417314241286092.

PMID: 39411269 PMC: 11475092. DOI: 10.1177/20417314241286092.

Trends of autoimmune liver disease inpatient hospitalization and mortality from 2011 to 2017: A United States nationwide analysis.

Wakil A, Muzahim Y, Awadallah M, Kumar V, Mazzaferro N, Greenberg P World J Hepatol. 2024; 16(7):1029-1038.

PMID: 39086532 PMC: 11287613. DOI: 10.4254/wjh.v16.i7.1029.

Prognostic factors for remission, relapse, and treatment complications in type 1 autoimmune hepatitis.

Sandusadee N, Sukeepaisarnjaroen W, Suttichaimongkol T Heliyon. 2020; 6(4):e03767.

PMID: 32382677 PMC: 7203077. DOI: 10.1016/j.heliyon.2020.e03767.

The Contribution of B Cells in Autoimmune Liver Diseases.

Taylor S, Assis D, Mack C Semin Liver Dis. 2019; 39(4):422-431.

PMID: 31226726 PMC: 6800599. DOI: 10.1055/s-0039-1688751.

References

Angulo P, Dickson E, Therneau T, Jorgensen R, Smith C, DeSotel C . Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol. 1999; 30(5):830-5. DOI: 10.1016/s0168-8278(99)80136-6. View

Habal F, Huang V . Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. Aliment Pharmacol Ther. 2012; 35(5):501-15. DOI: 10.1111/j.1365-2036.2011.04967.x. View

Zachou K, Gatselis N, Papadamou G, Rigopoulou E, Dalekos G . Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol. 2011; 55(3):636-646. DOI: 10.1016/j.jhep.2010.12.032. View

Sockalingam S, Blank D, Abdelhamid N, Abbey S, Hirschfield G . Identifying opportunities to improve management of autoimmune hepatitis: evaluation of drug adherence and psychosocial factors. J Hepatol. 2012; 57(6):1299-304. DOI: 10.1016/j.jhep.2012.07.032. View

Stellon A, Keating J, Johnson P, McFarlane I, Williams R . Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology. 1988; 8(4):781-4. DOI: 10.1002/hep.1840080414. View

Gleeson D, Heneghan M . British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011; 60(12):1611-29. DOI: 10.1136/gut.2010.235259. View

Chapman M, Webster G, Bannoo S, Johnson G, Wittmann J, Pereira S . Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. Eur J Gastroenterol Hepatol. 2012; 24(9):1051-8. PMC: 3584158. DOI: 10.1097/MEG.0b013e3283554bbf. View

Czaja A, Carpenter H . Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int. 2003; 23(2):116-23. DOI: 10.1034/j.1600-0676.2003.00810.x. View

Gregorio G, Portmann B, Karani J, Harrison P, Donaldson P, Vergani D . Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001; 33(3):544-53. DOI: 10.1053/jhep.2001.22131. View

10.

Lindor K, Gershwin M, Poupon R, Kaplan M, Bergasa N, Heathcote E . Primary biliary cirrhosis. Hepatology. 2009; 50(1):291-308. DOI: 10.1002/hep.22906. View

11.

Vuoristo M, Farkkila M, Karvonen A, Leino R, Lehtola J, Makinen J . A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology. 1995; 108(5):1470-8. DOI: 10.1016/0016-5085(95)90696-7. View

12.

Chazouilleres O, Wendum D, Serfaty L, Rosmorduc O, Poupon R . Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol. 2005; 44(2):400-6. DOI: 10.1016/j.jhep.2005.10.017. View

13.

Combes B, Emerson S, Flye N, Munoz S, Luketic V, Mayo M . Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology. 2005; 42(5):1184-93. DOI: 10.1002/hep.20897. View

14.

Tsuda M, Moritoki Y, Lian Z, Zhang W, Yoshida K, Wakabayashi K . Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology. 2011; 55(2):512-21. DOI: 10.1002/hep.24748. View

15.

Poupon R . Treatment of primary biliary cirrhosis with ursodeoxycholic acid, budesonide and fibrates. Dig Dis. 2011; 29(1):85-8. DOI: 10.1159/000324139. View

16.

van Hoogstraten H, Wolfhagen F, van de Meeberg P, Kuiper H, Nix G, Becx M . Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol. 1998; 29(3):417-23. DOI: 10.1016/s0168-8278(98)80059-7. View

17.

Johnson P, McFarlane I, Williams R . Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med. 1995; 333(15):958-63. DOI: 10.1056/NEJM199510123331502. View

18.

Feld J, Dinh H, Arenovich T, Marcus V, Wanless I, Heathcote E . Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology. 2005; 42(1):53-62. DOI: 10.1002/hep.20732. View

19.

De Groote J, Fevery J, Lepoutre L . Long-term follow-up of chronic active hepatitis of moderate severity. Gut. 1978; 19(6):510-3. PMC: 1412017. DOI: 10.1136/gut.19.6.510. View

20.

Jones D, Al-Rifai A, Frith J, Patanwala I, Newton J . The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up. J Hepatol. 2010; 53(5):911-7. DOI: 10.1016/j.jhep.2010.05.026. View